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Unmutated ancestorHumanmonoclonal antibody CH58 isolated from an RV144 vaccinee binds at Lys169 of the HIV-1 Env gp120 V2
region, a site of vaccine-induced immune pressure. CH58 neutralizes HIV-1 CRF_01 AE strain 92TH023 and
mediates ADCC against CD4+ T cell targets infected with CRF_01 AE tier 2 virus. CH58 and other antibodies
that bind to a gp120 V2 epitope have a second light chain complementarity determining region (LCDR2) bearing
a glutamic acid, aspartic acid (ED) motif involved in forming salt bridges with polar, basic side amino acid side
chains in V2. In an effort to learn how V2 responses develop, we determined the crystal structures of the
CH58-UA antibody unliganded and bound to V2 peptide. The structures showed an LCDR2 structurally pre-
conformed from germline to interact with V2 residue Lys169. LCDR3 was subject to conformational selection
through the afﬁnity maturation process. Kinetic analyses demonstrate that only a few contacts were responsible
for a 2000-fold increase in KD through maturation, and this effect was predominantly due to an improvement in
off-rate. This study shows that preconformation and preconﬁguration can work in concert to produce antibodies
with desired immunogenic properties.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The RV144 human immunodeﬁency virus (HIV) vaccine efﬁcacy trial
utilized a regimen combining recombinant canarypox vector ALVAC-
HIV (i.e. expressing HIV type 1 (HIV-1) Gag, Pro and membrane-linked
gp120 (vCP1521)) with HIV clades B and E gp120 envelope (Env) glyco-
protein (Rerks-Ngarm et al., 2009), and showed an estimated vaccine ef-
ﬁcacy of 31.2% (Rerks-Ngarm et al., 2009). Gp120 V1V2 antibodies were
correlates of decreased transmission risk for RV144 (Haynes et al.,
2012), primarily due to V2 antibodies (Karasavvas et al., 2012), and
high levels of antibody dependent cellular cytotoxicity (ADCC) in the ab-should not be construed as
nse or the Army.
), hayne002@mc.duke.edu
. This is an open access article undersence of high Env IgA levelswere inversely correlatedwith infection risk
(Haynes et al., 2012). A molecular sieve analysis demonstrated
Lys169 within the V1V2 region to be a site of immune pressure
with an estimated 48% vaccine efﬁcacy when the challenging HIV
strain matched the vaccine at this position (Rolland et al., 2012).
As a result, the gp120 V1V2 region has been of intense interest
owing to its immunogenic promise; however, V1V2 has proven difﬁcult
to characterize structurally. V1V2 has been observed in crystal struc-
tures in a variety of conformations. Bound to antibodies CH58 and
CH59 isolated from RV144 vaccinees, V2 peptides demonstrated helix
and loop-helix conformations respectively (Liao et al., 2013). When
presented in the context of a scaffold, the antibody-bound V1V2 has
adopted stranded conformations, notable not only because of the differ-
ing conformation but also because some of these antibodies were
broadly neutralizing (McLellan et al., 2011; Pancera et al., 2013). The
stranded V2 conformation was recapitulated in pre-fusion Env trimerthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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predominant responses to it as an antigen have beenwith glycan V3 an-
tibodies (Pancera et al., 2014). Thus interest remains in directing an im-
mune response against V1V2.
The V2 antibody CH58 has been biochemically and immunologically
characterized (Liao et al., 2013). CH58 mediates ADCC against tier 2
virus-infected CD4+ T cell targets (Haynes et al., 2012), has a footprint
at a site of immune pressure (gp120 Lys169) (Rolland et al., 2012),
and like PG9 and CH01 (Liao et al., 2013; McLellan et al., 2011) binds
the gp120 V2 region involving Lys169. CH58 cross-blocks binding of
PG9 and CH01 V1V2 broadly neutralizing antibodies (bNAbs) to Env,
but CH58 does not have bnAb activity and only neutralized the tier 1
HIV-1 CRF_01 AE strain 92TH023 that was included in ALVAC as a
prime vaccine immunogen (Liao et al., 2013; McLellan et al., 2011;
Rerks-Ngarm et al., 2009; Walker et al., 2009). Importantly, the
germline precursor to CH58 has been inferred and shows a relatively
low number of mutations leading to its functions: only 11 mutations
occurred from germline to mature antibody in both light and heavy
(Fab component) chains (Liao et al., 2013). Furthermore, CH58 has
been found to bear a key Glu–Asp (ED) pair in its second light chain
complementarity determining region (LCDR2) (Liao et al., 2013) that
is conserved among humans and rhesus macaques (Wiehe et al., in
press). This ED motif is predominantly present in V2 antibodies where
the negatively charged Glu and Asp side chains may form salt bridges
with the positively charged Lys and Arg side chains prevalent in variants
of the V2 sequence when presented as a linear epitope such as CH59,
HG107, and HG120 (Liao et al., 2013; Wiehe et al., in press). Moreover,
thepresence of this EDmotifwithin thepreconformed LCDR2 suggests a
pathway in which germline antibodies bearing it can recognize basic
residues within V2 (North et al., 2011; Wiehe et al., in press).
The relatively low number of mutations between the inferred,
unmutated ancestor of CH58 (CH58-UA) and the mature CH58 sug-
gested this relationship as ripe for study in the area of antibody lineages.
In terms of structure, it has been established that germline precursors
tend to display greaterﬂexibility in their idiotopes thanmature antibod-
ies, the rationale being that evolution tends to favor greater diversity
in immune responses so that it can react to new threats (Foote and
Milstein, 1994). Even through the maturation process, mature antibod-
ies can exist in an equilibrium of two or more structural isomers, only
one of which is the binding conformer; stated differently, mutations
that accumulate during antibody maturation can work cooperatively to
narrow conformational ensembles (Foote and Milstein, 1994; Manivel
et al., 2000; Zimmermann et al., 2006). In support of the notion of
promiscuous germline antibodies, it has been speciﬁcally found that
germline antibodies have HCDR3 sequences capable of adopting a wide
range of conformations (Babor andKortemme, 2009). However, this can-
not be taken to mean that mutations impacting immunogenicity must
necessarily occur within CDRs. In fact mutations that impact functional-
ity have been shown to occur in any of the CDRs as well as in the IgG
framework regions (Fera et al., 2014; Klein et al., 2013). Recently, it has
been demonstrated that antibody paratopes with CDRs preconﬁgured
(rigidiﬁed) through the maturation process are likely to experience
large afﬁnity gains throughmaturation (Schmidt et al., 2013). Themech-
anism for that particular study (the CH65-67 lineage of inﬂuenza HA
antibodies) was rigidiﬁcation of the antibody paratope through key so-
matic mutations at the HCDR3 anchorpoints (Schmidt et al., 2013).
Examining the detailed kinetics found within antibody afﬁnity mat-
uration, seminal work in the hapten system showed that the association
rate rather than afﬁnity was more important in afﬁnity maturation
(Foote and Milstein, 1994). In agreement with this, a study of various
antibodies from early primary and secondary responses suggested
that antibody maturation was a process driven to improve the associa-
tion but not dissociation step of binding (Manivel et al., 2000). Recently,
the study of the CH65-67 lineage of inﬂuenza HA antibodies demon-
strated a 30–40-fold increase in association rate with maturation
and a decrease in dissociation rate of signiﬁcantly lesser magnitude(Schmidt et al., 2013; Xu et al., 2014). There are also cases where im-
proved dissociation rates are the primary factor observed in afﬁnity
gains associatedwith antibodymaturation. This scenario has the beneﬁt
of being weighted toward antibodies with ﬂexible domains and HIV
antibodies in particular. Study of the evolution of the antiﬂuorescein
antibody 4-4-20 showed that the paratope was localized from a het-
erogeneous ensemble of conformations to a single conformation by
introducingmutations that acted cooperatively and over signiﬁcant dis-
tances to rigidify the protein (Zimmermann et al., 2006). Kinetic analy-
sis showed a modestly higher improvement in the dissociation rate of
this Ab–Ag complex compared to concomitant improvement in associa-
tion rate. Also, VH mutations were found that introduced H-bonding
between Ab and Ag that could account for this anchoring effect. Second,
kinetic analysis using a group of anti-(4-hydroxy-3-nitrophenyl)acetyl
monoclonal antibodies from within a single lineage revealed that
whereas association rates changed at most by a factor of two through
afﬁnity maturation, dissociation rates decreased by over an order of
magnitude (Sagawa et al., 2003). Recent work on antibodies against
IFNβ (a potential side effect of treatment with IFNβ for multiple sclero-
sis) showed that sera containing sustained neutralizing antibodies
(NAbs) demonstrated signiﬁcantly higher binding responses and slower
dissociation rates than sera containing transient NAbs and that the anti-
IFNβ antibodymaturation response acted over time to decrease dissoci-
ation rates thus increasing relative antibody binding afﬁnity (Gibbs
et al., 2014; Gibbs and Oger, 2008). Importantly, kinetic analysis of IgG
framework region reversion mutations in HIV-1 bNAbs VRC01, NIH45-
46, 12A21, and 3BNC117 (Scheid et al., 2011; Wu et al., 2011; Zhou
et al., 2010, 2013) showed that the loss of afﬁnity appeared to be pri-
marily due to an increased dissociation rate (Klein et al., 2013). Lastly,
the same effect was shown for the unmutated ancestor of the anti-
gp41 MPER antibody 2F5 (Alam et al., 2011).
Given the fact that CH58 is only modestly mutated from its inferred
ancestor CH58-UA, the pair presented itself as an ideal study in antibody
lineages to explore these issues of structural rigidity, preconﬁguration,
preconformation, and binding afﬁnity improvements. In addition, inter-
est in CH58 and similar antibodies against linear V2 epitopes remains
high because even though their neutralization capacities are limited,
they are easy to induce (Haynes et al., 2012; Liao et al., 2013;
Rerks-Ngarm et al., 2009; Wiehe et al., in press); whereas broadly neu-
tralizing antibodies are not induced by currentHIV-1 vaccine candidates
(Mascola and Haynes, 2013). For this study, we have determined
the crystal structures of CH58-UA in both its unliganded state and in
complex with a gp120 peptide representing the nominal V2 epitope.
Comparative analysis of these structures in concert with likewise
unliganded and liganded mature CH58 structures showed that of the
11 total mutations from unmutated ancestor, nine mutations occurred
in CDRs and only a subset of those show any direct impact on contacts
with antigen. Importantly, our kinetic analyses those few contacts
were responsible for a 2000-fold increase in KD for the mature CH58
over CH58-UA, and this effect was predominantly due to a largely de-
creased off-rate that could be related back to speciﬁc contacts gained
by virtue of just a few functionally important mutations.
2. Materials & methods
2.1. Protein production
The Fab fragment of CH58-UA was produced recombinantly as pre-
viously described (Nicely et al., 2010). In short, Fab chains were gener-
ated by PCR using light and heavy chain genes as templates with
appropriate primer pairs, and cloned into pcDNA3.1/hygro (Liao et al.,
2006). Recombinant Fabs were produced in 293F cells by transient
transfection then puriﬁed using methods described previously (Nicely
et al., 2010). For structural and SPR studies, after afﬁnity capture using
LambdaCapture (BAC), the Fab was further puriﬁed via gel ﬁltration
chromatography using a HiLoad 26/60 Superdex 200 pg 26/60 column
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NaN3. Fab peak elution fractions were pooled and exchanged into
ddH2O via ﬁve dilute-concentrate cycles and brought toﬁnal concentra-
tions of 15.0 mg/mL.
Gp120165–186 (LRDKKQKVHALFYKLDIVPIED) wild-type and Ala-
substituted peptides were originally synthesized for ELISA by CPC
Scientiﬁc, and a similar peptide albeit with a biotin tag (gp120166–186;
“171”) was synthesized for SPR experiments. Gp120165–182 (LRDKKQ
KVHALFYKLDIV), gp120165–182 Leu179Ala (LRDKKQKVHALFYKADIV)
and gp120165–182 Leu179Ala,Ile181Ala (LRDKKQKVHALFYKADAV)
were synthesized with C-terminal linkers (−GGGK–) and biotin tags
for BLI experiments, and the best binding of the three synthesized
with an acetylated N-terminus and amidated C-terminus for crystallog-
raphy to be used to form a complex with CH58-UA where it was
dissolved in neat DMSO to 100 mg/ml then added to Fab in solution
at a 1:3 Fab:peptide molar ratio prior to setting of crystallization
experiments.
2.2. Surface plasmon resonance (SPR)
Epitope mapping experiments in SPR were performed on a BIAcore
4000 (BIAcore Inc, Piscattaway, NJ) instrument at 25 °C. Using a Series
S CM5 chip, wild-type and Ala-substituted peptides were amine-
coupled directly on the chip surface. Data analyses were performed
using the Biacore 4000 evaluation and BIAevaluation 4.1 software
(BIAcore) as previously described (Alam et al., 2007, 2011). Monoclonal
antibodies were used in these experiments. Binding responses of the
irrelevant respiratory syncytial virus (RSV) antibody Synagis were used
to subtract out responses due to non-speciﬁc interactions as standard
good practice.
2.3. BioLayer interferometry (BLI)
BLI measurements were made using a ForteBio OctetRed 96 instru-
ment and streptavidin sensors at 25 °C. Data analyses were performed
using ForteBio data analysis 7 software. The gp120165–182 peptide
sensors were prepared by dipping streptavidin sensors into wells con-
taining biotinylated gp120165–182 peptides (5 μg/ml) for 300 s. The
peptide-loaded sensors were washed in PBS buffer (pH 7.4) for 60 s
before obtaining baseline. In the screening experiments, binding of the
CH58-UA and mature CH58 Fabs (at 10 μg/ml) to gp120165–182 peptide
(wild-type and Ala mutants) sensors were monitored for 300 s and
the dissociation was followed for 300 s. The inﬂuenza hemagglutinin-
speciﬁc antibody CH65 was used as negative control to subtract out
binding due to non-speciﬁc interactions with sensors as standard good
practice. The binding signal during the last 20 s of the dissociation
phase was averaged and used to calculate normalized binding. The
afﬁnity measurements of CH58-UA and mature CH58 Fabs to the
wild-type and Leu179Ala,Ile181Ala mutant peptides were carried out
by performing binding titrations (Fab concentrations ranged from 1 to
20 μg/ml). The gp41 MPER speciﬁc 13H11 Fab (1–20 μg/ml) binding to
the wild-type and Leu179Ala,Ile181Ala mutant peptides sensors was
used in parallel to subtract out binding due to non-speciﬁc interactions
with the sensors. The subtracted binding curves were ﬁtted globally to
a 1:1 binding model to obtain association (ka), dissociation (kd) rate
constants and the apparent dissociation constant (KD).
2.4. Circular dichroism spectroscopy
The circular dichroism (CD) spectra of the WT and mutant
gp120165–182 peptidesweremeasured on an Avivmodel 202 spectropo-
larimeter using a 1 mm path length quartz cuvette. The peptides were
solubilized in PBSF buffer (19 mM phosphates pH 7.4, 100 mM NaF) at
0.1 mg/ml concentration and CD spectra were recorded at 25 °C. Three
scans of the CD spectra of each peptidewere averaged and the CD signal
from PBSF buffer was subtracted out.2.5. Crystallography
Unliganded CH58-UA Fab was crystallized in a low ionic strength
screen (Harris et al., 1995) in a drop composed of 0.3 μl 15 mg/ml pro-
tein plus 0.3 μl 25 mM MES pH 6.0, 1.5% PEG 3350 over a reservoir of
50 μl 24% PEG 3350 at 20 °C. These crystals were cryoprotected using
a solution of 30% PEG 3350, 30% ethylene glycol. Crystals of CH58-UA
Fab–gp120165–182 Leu179Ala,Ile181Ala were observed over a reservoir
of 0.2 M calcium acetate hydrate, 20% PEG 3350 in a drop composed
of 0.2 μl 12 mg/ml protein plus 0.4 μl reservoir. These crystals were
cryoprotected using a solution of 25% PEG 3350, 30% ethylene glycol.
Diffraction data were collected at SER-CAT with an incident beam of
1 Å in wavelength. Datasets were reduced in HKL-2000 (Otwinowski
and Minor, 1997). Matthews analysis suggested two Fabs in the
asymmetric unit of the unliganded CH58-UA structure and only one in
that of the liganded CH58-UA structure (Matthews, 1968). The struc-
tures were phased by molecular replacement in PHENIX (Terwilliger
et al., 2008) using as source models the mature CH58 Fab structure
(Liao et al., 2013). Rebuilding and real-space reﬁnements were done
in Coot (Emsley et al., 2010) with reciprocal space reﬁnements in
PHENIX (Adams et al., 2010) and validations in MolProbity (Lovell
et al., 2003).
2.6. Accession codes
Coordinates and structure factors have been deposited in the Protein
Data Bank under accession codes 4RIR (CH58-UA), and 4RIS (CH58-UA
complex).
3. Results
3.1. IncreasedKDwithmaturationwas primarily due to off-rate improvement
The nominal epitope for the CH58-UA antibody was mapped in
surface plasmon resonance (SPR) using AE.CM244V2-171 peptide
(gp120165–186 = LRDKKQKVHALFYKLDIVPIED) and its sequentially
Ala-substituted derivatives (Fig. 1A). The results agreed with those
seen for the mature CH58 (Fig. 1B) except that some Ala substitutions
produced notably higher binding responses to CH58-UA (Liao et al.,
2013). The three V2 residues that conferred the strongest binding
to CH58-UA when mutated to Ala were Leu179 (a ~ 6.1-fold increase
in the SPR binding response compared to wild-type peptide), Ile181
(a ~ 3.9-fold increase in the same), and Val182 (a ~ 3.4-fold increase
in the same).
The SPR epitopemapping data served as a basis for a second round of
targeted Ala mutations. The Leu179Ala, Ile181Ala, and Val182Ala muta-
tions were screened singly and in combinations using biolayer interfer-
ometry (BLI) with a modestly shorter gp120165–182 peptide to identify
improved potential binding partners for a liganded CH58-UA structure
(Fig. 2, Tables S1–S3). SPR was performed with monoclonal antibodies
whereas BLI was performedwith Fabs. Fabs are known to displayweak-
er binding to antigens compared to mAbs owing to avidity effects. Thus
it was important to include experiments ofmature CH58 (mAb or Fab as
appropriate) binding wild-type peptide to serve as a point of reference.
In our BLI experiments, we observed an average KD value of 4.6 nM for
wild-type gp120 peptide binding mature CH58 compared to a 11.0 μM
KD for the same peptide binding to the CH58-UA (Table S1). This
represented an approximate 2000-fold gain in bindingwithmaturation.
In detail, the association rate (ka) for wild-type gp120 peptide in
binding mature CH58 had an average value of 6.6 × 104 M−1 s−1
compared to one of 1.6 × 104M−1 s−1 for CH58-UAwith the same pep-
tide, representing a modest 4-fold gain of on-rate with maturation
(Table S2). Compare that to the dissociation rate (kd) for wild-type pep-
tide with mature CH58 of 3.0 × 10−4 s−1 versus one of 1.7 × 10−1 s−1
for the same peptide with CH58-UA, a ~600-fold decrease in off-rate.
Fig. 1. Epitope mapping of CH58-UA and CH58 mAbs. A) The epitope for the CH58-UA
monoclonal antibody was mapped in SPR using sequentially Ala-substituted AE.CM244V2-
171 peptides (gp120166–186). The response from each experiment was normalized to that
ofwild-typepeptide for comparative purposes. The graph is truncated at a two-fold response
ratio to emphasize losses of binding. The substitutions that gave responses above two-fold
are speciﬁed over their columns. The asterisk next to Ala174 indicates that itwas substituted
with Glu to distinguish that peptide from wild-type and to impart a contrasting charge
character to the predominantly positively charged V2 peptide N-terminal region. B) The
epitope for the mature CH58 mAb was previously mapped in ELISA (Liao et al., 2013) and
is included here for comparative purposes. C) Example SPR sensograms are shown for
some of the Ala-substituted peptides in the CH58-UA study. Wild-type peptide binding
levels were taken into account to normalize data for presentation in this single plot.
716 N.I. Nicely et al. / EBioMedicine 2 (2015) 713–722Thus the improved KD values from CH58-UA to mature antibody were
predominantly a result of decreasing off-rates.
In terms of ﬁnding a peptide suitable for structural workwith CH58-
UA, the double Ala mutant Leu179Ala,Ile181Ala conferred the largest
binding enhancement to CH58-UA (Fig. 2B). The average association
rate for this mutant peptide with CH58-UA was 9.5 × 105 M−1 s−1
compared to one of 1.6 × 104 M−1 s−1 for wild type peptide,
representing a 60-fold increase in on-rate (Table S3). In contrast, the
average dissociation rates were 7.2 × 10−2 s−1 for CH58-UA with the
mutant peptide and 1.7 × 10−1 s−1 for wild-type peptide, indicating
a mere 2-fold decrease in off-rate. However, the enhanced on-rate
resulting from these two mutations manifested in an average KD of
0.9 μM compared to one of 11.0 μM for the wild-type peptide. This
approximate ~10-fold increase in binding was sufﬁcient to generate
a complex suitable for crystallography. To examine whether the en-
hanced afﬁnity of the Leu179Ala,Ile181Ala double mutant might be
due to any change toward preferred structure of the peptide itself, we re-
corded the circular dichroism (CD) spectra of wild-type gp120165–182,
gp120165–182 Leu179Ala and gp120165–182 Leu179Ala,Ile181Ala peptides
(Fig. 3). All three peptides exhibited similar CD proﬁles. Therefore, the
selected mutations (single and double) did not appear to affect peptide
secondary structure in solution. Lastly, an alignment of 4907 Env
sequences from the LANL HIV sequence database (www.hiv.lanl.gov)
showed that alanines at the 179, 181 and 182 positions in the V2 region
are rare or non-existent with frequencies of 0.77% (38/4907), 0%
(0/4907) and 1.61% (79/4907), respectively.
3.2. The ED motif is part of a pre-conﬁgured LCDR2
The crystal structures of unliganded CH58-UA Fab and CH58-UA Fab
in complexwith gp120165–182 Leu179Ala,Ile181Ala peptide were solved
by molecular replacement and reﬁned to resolutions of 2.5 and 2.3 Å,
respectively (Table 1). The statistics for model reﬁnements were typical
of other crystal structures at these resolutions (Urzhumtseva et al.,
2009). Notably, HCDR3 was ordered in the liganded CH58 structure
and disordered in the unliganded CH58 structure (Liao et al., 2013); in
comparison, HCDR3 was ordered in the liganded CH58-UA structure
though in a different conformation than that seen with the mature
CH58. HCDR3 was also ordered in the unliganded CH58-UA structure
although it appeared that crystal contacts played a role in helping to sta-
bilize the observed conformation. TheHCDR3 conformational difference
was reﬂected in the RMSD values for pairwise structural comparisons:
the RMSD between the Fv fragments of CH58-UA and mature CH58
was 0.284 Å, whereas the RMSD between the unliganded and liganded
CH58-UA structures was 0.963 Å.
The conserved EDmotif is present in LCDR2 of both the CH58-UA and
CH58 antibodies at residue positions Glu50 and Asp51 (Figure S1).
LCDR2 adopted the same overall conformation in the unliganded and
liganded forms of both CH58-UA and CH58 (Fig. 4). While LCDR2 is the
least structurally variable of the six CDRs (North et al., 2011), the ED
motif was found to occur in only two human germline light chain
sequences, both Vλ (3–10 and 6–57), and both bearing the ED motif at
one amino acid position into the LCDR2 region (xEDxxxxx). This posi-
tions both side chains to orient outward from the core IgG fold and
into the antibody paratope (Fig. 4A). In terms of speciﬁc interactions,
the CH58-UA liganded structure showed a salt bridge of 2.8 Å between
Lys169(V2) and Glu50(L) (Fig. 4B). The amine functional group on the
Lys169 side chain additionally found a favorably electronegative envi-
ronment for binding courtesy of Tyr32 in LCDR1 and Asp100B,
Ser100C, Ser100D, and the backbone carbonyl of Gly100E in HCDR3.
Asp51(L) formed a salt bridge with Lys168(V2) also 2.8 Å in length
(Fig. 4B), and likewise the amine functional group of the Lys168(V2)
side chain found favorable electrostatic interactions with the carbonyls
of Ala29(L) and Asn31(L) in LCDR1. None of these LCDR1 and LCDR2 in-
teractions changed appreciably in the mature CH58 complex (Fig. 4B)
(Liao et al., 2013).
Fig. 2. Binding of CH58-UA and CH58 to wild-type and Ala-substituted gp120165–182 peptides. A) Results from BLI showing binding between CH58-UA Fab fragment and gp120165–182 V2
peptide variants. B) The shift inwavelength during the last 20 s of the dissociation phase of CH58-UA binding to the peptides shown in panel Awas averaged and normalized to that ofwild
type peptide for comparative purposes. The error bars denote the standard deviation in the values determined from triplicatemeasurements. C) Representative BLI sensograms are shown
for detailed kinetic experiments with wild-type gp120165–182 V2 peptide and CH58-UA Fab. Likewise, D) mature CH58 Fabwith wild-type peptide and E) CH58-UA Fabwith gp120165–182
Leu179Ala,Ile181Ala. In these experiments, the gp41MPER-speciﬁc 13H11 Fabwas used as negative control to subtract non-speciﬁc binding to the peptide as standard good practice. The
ka, kd and derived KD valueswere obtained by global ﬁtting of speciﬁc binding sensograms to a 1:1 bindingmodel. Examplemeasurements are reported in these panels. Average KD values
are reported in the text for duplicate (CH58-UA Fab) and triplicate (CH58 Fab) measurements.
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In total, there were ﬁve key salt bridges between antibody and
peptide in the liganded CH58 structure (Liao et al., 2013). Three ofFig. 3. CD data for gp120165–182 peptide and two of its Ala-substituted variants. CD
spectra for the gp120165–182 peptide and its Ala-substituted variants Leu179Ala and
Leu179Ala, Ile181Ala.these salt bridges – Lys168(V2) to Asp51(L), Lys169(V2) to Glu50(L),
and Lys178(V2) to Asp54(H) – were present in the liganded CH58-UA
complex. The two additional salt bridges, Lys171(V2) to Asp31(L) and
Asp180(V2) to Arg28(H), were formed during afﬁnity maturation
(Fig. 5). The light chain residue Asp31(L) was an Asn in CH58-UA. The
Asn residue formed a preferential H-bond with the nearby light chain
residue Arg25(L), and this intra-chain association was uninterrupted
upon introduction of ligand (Fig. 5A). However, the mature antibody
had an Asp residue in place of the germline Asn, and the Asp side chain
accommodated a bifurcatedH-bond tobothArg25(L) andV2peptide res-
idue Lys171(V2). The second noted salt bridge, Asp180(V2) to Arg28(H),
represented a different scenario. In CH58-UA, Ser28(H) lacked both the
reach and the electrostatic character to establish a salt bridge with
Asp180(V2) (Fig. 5B). In the mature CH58, the Arg side chain rectiﬁed
both these problems and established an H-bond with Asp180(V2). It
is likely that this interaction anchored the C-terminal portion of the V2
peptide in the mature complex, and conversely failed to anchor it in the
CH58-UA complex thus suggesting why the peptide C-terminus is disor-
dered in that structure. Lastly, this salt bridge with Asp180 is potentially
signiﬁcant in that this residuewas part of the putativeα4β7 binding inter-
face with gp120 (Arthos et al., 2008). The tripeptide motif LDVwas iden-
tiﬁed as part of the α4β7 binding interface, and this motif appears in
gp120 V2 and the liganded CH58 structure as LDI (gp120179–181) (Liao
et al., 2013; Zeller et al., 2001). The salt bridge at Asp180 is indeed likely
Fig. 4. LCDR2 and ED motif interactions. A) The unliganded structures of CH58-UA and
mature CH58 (with superimposed V2 peptide) showed that the Lys169 salt bridge with
Glu50 in LCDR2 was pre-conﬁgured. In contrast, the disordered HCDR3 (indicated by
spheres) offered no stable contacts. B) The liganded CH58-UA andmature CH58 structures
showed that the hydrogen bond between Gly100E(H) and Lys169(V2) required ordering
of HCDR3, whereas the ability to form the salt bridge between Glu50(L) in LCDR2 and
Lys169(V2) was pre-conformed in CH58-UA.
Table 1
Data collection and reﬁnement statistics for the structures.
Structure CH58-UA CH58-UA–gp120165–182
Leu179Ala,Ile181Ala
Data collection
Space group: P21a P21
Cell dimensions
a, b, c (Å): 53.7, 103.7, 101.2 55.7, 53.9, 73.6
α, β, γ (°): 90.0, 100.5, 90.0 90.0, 108.9, 90.0
Resolution (Å): 50–2.5 (2.54–2.50) 50–2.3 (2.34–.30)
Rmerge (%): 13.1 (42.6)b 11.4 (36.6)
bI/σN 7.9 (2.0) 19.0 (3.4)
Completeness (%): 97.4 (93.9) 99.9 (99.5)
Redundancy: 3.3 (3.0) 6.1 (5.2)
Reﬁnement
Total # reﬂections: 36,924 18,762
Unique # reﬂections: 33,979 18,258
Rwork/Rfree (%): 22.0/28.9 (30.8/43.0) 16.1/24.6 (19.3/31.4)
Average B factor (Å2): 26.35 30.25
Nonhydrogen atomsc: 6578 3461
Water molecules: 112 239
R.M.Scuu deviations
Bond lengths (Å): 0.005 0.007
Bond angles (°): 0.943 1.136
ψ, φ favored (%): 96.6 96.2
ψ, φ allowed (%): 3.0 3.4
zψ, φ outlying (%): 0.4 0.5
a This crystal had two Fabs in the asymmetric unit.
b Values in parentheses are for the highest resolution shells.
c Not including water molecules.
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ed that CH58 can block α4β7 binding to V2 (Liao et al., 2013).
3.4. Conformational selection of LCDR3
The paratope of liganded CH58-UA displayed a pocket in which the
hydrophobic side chain of Leu175(V2) bound (Fig. 6A). This pocket
was present in both the unliganded and liganded mature structures as
well, though LCDR3 was in a slightly different conformation (Fig. 6B).
However, the Leu175(V2) hydrophobic pocket was not present in the
paratope of the unliganded CH58-UA because LCDR3 adopted a confor-
mation there which put the side chain of Tyr91(L) in a position that
eliminated the character of the pocket in terms of both its shape and
its hydrophobicity; in essence, the Tyr91(L) side chain in the unliganded
CH58-UA structure caused a steric clash with Leu175(V2) of overlaid
peptide (Fig. 6A). Thismay suggest that thematuration process selected
an optimal conformation for LCDR3 that would not require an energetic
penalty associated with conformational change on binding. It is noted
that movement in the Tyr91(L) side chain as it appeared in the
unliganded CH58-UA structure required concomitant movement of
the side chain of Tyr100G in HCDR3. Tyr100G exhibited a different
rotamer in the mature CH58 structure that was likely inﬂuenced by
the proximity of Phe100I(H) which in turn was limited by Gly35(H).
Heavy chain residue 35 is the site of a Gly→ Val mutation (Figure S1).
Thus it is apparent that structural rearrangements in LCDR3 may well
be linked to those in HCDR3 through the anchorpoints of each CDR
andwith both affected in someway bymutations occurringwithmatu-
ration; however as HCDR3was disordered in the ligandedmature CH58
structure (Liao et al., 2013), it is impossible to draw deﬁnitive conclu-
sions about HCDR3 and its role in ligand binding. However, it seems
clear that this was a case of conformational limiting for LCDR3 (Boehr
et al., 2009; Foote and Milstein, 1994; Jimenez et al., 2003; Manivel
et al., 2000; Zimmermann et al., 2006).
4. Discussion
The overall purpose of the study was to scrutinize the development
of the CH58 antibody from its germline precursor in the context ofunderstanding V2 immonogenic responses. The increased afﬁnity
of the mature CH58 antibody over its inferred unmutated ancestor
CH58-UA appeared to depend in part on tuning of local interactions.
The introduction of new salt bridges as well as mutations from afﬁnity
Fig. 5. Speciﬁc polar interactions between antibody and epitope gained throughmaturation. A) Asp31(L) inmature CH58 forms a salt bridgewith Lys171(V2) and is additionally stabilized
by a salt bridgewith Arg25(L). In CH58-UA the salt bridgewith Arg25(L) is present as are the proximity and geometry necessary to interactwith V2, except that Asn31(L) clearly lacks the
functional group necessary. B) Arg28(H) in mature CH58 forms a salt bridge with Asp180(V2), helping to anchor the C-terminus of the V2 peptide. However in CH58-UA, Ser28(H) is
unable to make any such interaction with V2 peptide. In fact the C-terminus of the peptide in the CH58-UA complex structure is disordered without this interaction, and Asp180(V2)
is not present in the structure as a result.
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throughout theparatope, includingmodest but effective conformational
selections and rotamer adjustments. The conformation of LCDR2 con-
taining the ED motif was nearly identical in all CH58 lineage structures
— CH58-UA and mature CH58, unliganded and liganded. The ED motif
also appeared in the CH59 antibody lineage, where Asp51(L) formed
a salt bridge with Lys169(V2) (Liao et al., 2013). Similar to the CH58
lineage structures, the amine functional group of Lys169wasmet favor-
ably in theV2 antibody CH59 paratope by electronegativity conveyed by
Asp51(L) in LCDR2 and Ser66(L), as well as the backbone carbonyls of
Leu28(L) and Pro29(L). The low level of conformational diversity in
LCDR2 (North et al., 2011) and the invariance of the positioning of the
EDmotif within the LCDR2 germline alleleswithinwhich it appears rep-
resent two levels of conservation (structure and sequence) for this key
motif. Moreover, preconﬁguration of an antibody paratope canmitigate
the energetic penalty paid upon association between the mature anti-
body and its antigen (Schmidt et al., 2013). Conceptually, the same pen-
alty is avoided when an element of the paratope is preconformed from
germline, as is the case with LCDR2 in CH58-UA, and when the large
gain in afﬁnity for antigen (KD) through maturation is predominantly
attributable to a decreased off-rate (kd). Preconformed motifs in
germline alleles tend to be preferred in anti-HIV antibodies as they
mimic HIV epitopes or otherwise present favorable structural paratope
features. CH58 and antibodies like it are unique fromCD4 binding site or
gp41MPER antibodies in that restricted pairing of light and heavy chain
alleles occurs at the light chain V gene level (Wiehe et al., in press). For
example, with VRC-01, there is a steric requirement that the LCDR3 be
short, but that is independent of the light chain V gene used since its
particular LCDR3 depends on rearrangement, not just the V gene used;
whereas, in instances where LCDR2 bears the ED motif (CH58 and
CH59), the motif encoded strictly by the V gene.
Mutations in both the CDRs and the framework region played im-
portant roles in conformational selection of LCDR3 in the CH58 lineage,
reﬂecting previous research showing that the inﬂuenza antibody CH65
lineage rigidiﬁed its ﬂexible HCDR3 through maturation (Schmidt
et al., 2013). The importance of somatic mutations may be in their abil-
ity to foster a certain degree of ﬂexibility necessary to promote optimal
antigen binding (Klein et al., 2013). For instance, a recent report of aframework mutation in the anti-HIV antibody lineage producing
CH103 that culminated in a shift between the L and H domains (Fera
et al., 2014). With CH58, a network of structural changes involving
such mutations acted to conﬁgure the conformation of LCDR3 from
one that would only tolerate antigen binding to one that was optimal
for it.
The lineage producing CH58 showed an afﬁnity gain primarily being
due to improvements in kd. The dissociation rate improved in going
from CH58-UA to CH58 almost 600-fold compared to an association
rate improvement of only about 4-fold, the net result being an afﬁnity
gain from 11.0 μM to 4.6 nm. The anti-HIV antibodies VRC01, NIH45-
46, 12A21, and 3BNC117 displayed similar patterns. They did not have
values reported for on- and off-rates; however, it was qualitatively
evident frompublished SPR rawdata that afﬁnity gainswithmaturation
in all four cases were primarily due to improvements in off-rate (Klein
et al., 2013). CH59 showed a dramatically improved off-rate compared
to its inferred unmutated ancestor (1.5 × 10−4 s−1 for the mature
CH59 compared to 7.4 × 10−2 s−1 for CH59-UA) that was entirely
responsible for the afﬁnity gain observed in the mature antibody
(Wiehe et al., in press). The unmutated ancestor of the gp41 MPER
antibody 2F5 was inferred to stem from one of two germline variants,
either of whichwas equally likely owing to the high degree of mutation
observed in 2F5 alongwith uncertainty inherent to the inference meth-
od (Alam et al., 2011). 2F5-UA variant 1 bore residue D54(H) in its
HCDR2 whereas variant 2 showed N54(H) (Alam et al., 2011). The
mature 2F5 had D54(H) like variant 1. The association rates of variant
1 andmature were similar (1.8 × 104M−1 s−1 vs 2.7 × 104M−1 s−1 re-
spectively). Variant 2 had an association rate an order of magnitude
lower (3.9 × 103M−1 s−1). However, both UA variants had dissociation
rates comparable (1.1 × 10−3 s−1 for variant 1, 2.6 × 10−3 s−1 for
variant 2), whereas the mature 2F5 antibody had a dissociation rate
two orders of magnitude lower (3.1 × 10−5 s−1). It was this signiﬁcant
decrease in the off-rate that was found to drive the higher afﬁnity that
the mature had for antigen. Of note, the uncertainty between the
two 2F5-UA variants illustrates either of two important concepts in
the present study: either the higher association rate of UA variant 1
belied the beneﬁt of preconformed paratope features because 2F5 relies
on D54(H) along with D56(H) to establish key salt bridges with its
Fig. 6. LCDR3 conformational ordering through maturation. A) In CH58-UA, LCDR3
exhibited different conformations between its unliganded and liganded states. In a
superposition between the unliganded (green) and liganded (cyan and orange as labeled)
structures, Tyr91(L) in the unliganded conformation clashed with overlaid Leu175(V2)
from the complex structure. HCDR3 is additionally indicated for reference. B) In the
mature CH58, LCDR3 exhibited the same conformation in both unliganded and liganded
states, and this conformation differed from either of those observed in the CH58-UA struc-
tures. HCDR3 is also labeled here, though it was disordered in the unliganded mature
CH58 structure (Liao et al., 2013).
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and other speciﬁc contacts gained in thematuration process help to dra-
matically improve off-rate between Ab–Ag thus increasing afﬁnity.
In looking at non-HIV antibody lineage afﬁnity gains, ﬁtting the
same category of predominant off-rate improvements is a series of
anti-(4-hydroxy-3-nitrophenyl)acetyl antibodies where the most ma-
ture member of the set had a 5-fold improved off-rate over the least
mature member, with a worse on-rate for the same pairwise compari-
son (Sagawa et al., 2003). Though less exemplary, the antiﬂuorescein
antibody 4-4-20 showed a 6-fold improved off-rate and a 2-fold on-
rate over its germline (Zimmermann et al., 2006). Also, anti-IGNβ
antibodies in the sera of patients with sustained IGNβ treatment were
found on average to have improved off-rates compared to the sera
from patients transiently treated (Gibbs et al., 2014). In contrast, the
ﬂu antibodies CH65 and CH67 showed afﬁnity gains over their shared
unmutated ancestor that were predominantly due to on-rate improve-
ments (Schmidt et al., 2013). More detailed kinetic analyses are needed
before the ﬁeld can draw signiﬁcant conclusions on the topic, but it may
be that antibodies with elements of preconformation and key Ab–Ag
contacts gained throughmaturation in their idiotopes tend to be driven
by improvements in off-rate, whereas antibodies with paratopes that
require structural ordering (preconﬁguration) in addition to the previ-
ous factors see comparably higher gains in on-rate.
HIV broadly neutralizing antibodies tend to show high levels of
mutation from germline and are rare or difﬁcult to induce (Kwong
and Mascola, 2012; Mascola and Haynes, 2013). In contrast, modestly
mutated antibodies from the RV144 vaccine efﬁcacy trial produced the
strongest ADCC responses (Bonsignori et al., 2012; Haynes et al.,
2012). CH58 is not a broadly neutralizing antibody, however it is a facile,
dominant-response antibody induced by the RV144 vaccine (Haynes
et al., 2012; Karasavvas et al., 2012; Liao et al., 2013). In neutralizing
isolated strains and mediating ADCC, it may confer some protective
beneﬁt. Moreover, its ability to block interaction between gp120 and
α4β7 suggests that although many HIV-1 strains do not appear to bind
α4β7 (Perez et al., 2014), CH58 and antibodies like it may restore the
natural proliferation of B cells that is subverted by any α4β7 interaction
(Jelicic et al., 2013; Tassaneetrithep et al., 2014). Thus it is hoped that
vaccine regimens can be developed to include CH58-like responses. In
this regard, a recent publication has shown that the combination of
CH58 with 7B2, a gp41 immunodominant loop antibody, can increase
the capture of infectious virions (Liu et al., 2014).
In summary, structural and kinetic analyses of CH58-UA and ma-
ture CH58 showed that a key feature of the paratope, LCDR2, was
preconformed for antigen recognition at a site of immune pressure
(V2 Lys169) and presented a conserved motif optimal for interacting
with a reciprocal motif in gp120 V2. Another factor in maturation
was conformational selection of LCDR3, resulting in an optimal binding
site for antigen. A third factor was the gain of salt bridges between an-
tibody and antigen speciﬁc to mutations in the antibody that occurred
with maturation. The primary goal of follow-up studies to RV144 is
learning how to improve on it. One such improvement would be to
increase the breadth of V2 responses. To learn how tomanipulate V2 re-
sponses, it is key to know how they develop. In the case of the lineage
producing CH58, it is clear that speciﬁc residues within the V2 region
are critical contacts with both the germline ancestor and the mature
antibody.
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